Geron Corporation , a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that five abstracts ? one oral and four poster ...

Findings further demonstrate the effectiveness of Roche's approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline signals progress ...

“The data ... analysis from the phase Ib CAMMA-1 study shows investigational cevostamab in combination with pomalidomide and dexamethasone induces high ORR, very good partial response (VGPR) or better ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading hematology portfolio ...